3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Non-Muscle Invasive Bladder Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Diseases
1
Infections
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
COVID-19
1
Breast Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Adenocarcinoma Of Esophagus
1
Interventions
Cisplatin
115
Radiotherapy
83
Paclitaxel
77
Fluorouracil
61
Carboplatin
41
Drug Therapy
34
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
Oxaliplatin
23
Neoadjuvant Therapy
23
toripalimab
22
sintilimab
19
camrelizumab
19
Radiation
19
Esophagectomy
17
Capecitabine
17
130-nm albumin-bound paclitaxel
17
Surgical Procedures, Operative
15
Leucovorin
15
Nivolumab
14
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
anlotinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Squamous Cell Carcinoma
×
monalizumab
×
Clear all
NCT03307941
2017-12-19
ARTEMIS-Eso
Jules Bordet Institute
Phase 1/2
Withdrawn